The news is by your side.

join forces

Novartis, Pfizer join forces on potentially lucrative fatty liver disease

ZURICH/NEW YORK: Novartis and Pfizer are teaming up to develop treatments for a liver disease many drug companies believe will become a hugely lucrative market, as it is tied to the obesity and diabetes epidemics. The Swiss and US drugmakers announced on Monday that they will collaborate to develop combination therapies involving medicines they have been working on separately to treat nonalcoholic steatohepatitis, or NASH. Though hardly a household name, the progressive fatty liver disease with no approved treatments…